ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer

A caller investigation of a signifier 3 objective proceedings recovered that the targeted cause daraxonrasib improved endurance compared with modular chemotherapy crossed aggregate groups of patients with precocious pancreatic cancer, including those with antithetic RAS mutations and those without an identified RAS mutation.